MindWalk (NASDAQ:HYFT) Upgraded at Zacks Research

Zacks Research upgraded shares of MindWalk (NASDAQ:HYFT) from a strong sell rating to a hold rating in a report published on Monday morning,Zacks.com reports.

Separately, Weiss Ratings began coverage on MindWalk in a report on Wednesday, January 14th. They issued a “sell (d-)” rating for the company. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Reduce”.

MindWalk Trading Up 5.1%

Shares of HYFT opened at $1.45 on Monday. The stock has a market cap of $66.93 million, a P/E ratio of -2.42 and a beta of 0.51. The company has a debt-to-equity ratio of 0.18, a current ratio of 4.19 and a quick ratio of 4.09. MindWalk has a 1-year low of $0.27 and a 1-year high of $3.25.

Hedge Funds Weigh In On MindWalk

A number of large investors have recently bought and sold shares of the business. Bank of Montreal Can lifted its holdings in MindWalk by 81.0% during the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after buying an additional 24,500 shares during the period. Renaissance Technologies LLC raised its position in shares of MindWalk by 8.4% in the 4th quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock worth $435,000 after acquiring an additional 18,600 shares in the last quarter. Jane Street Group LLC lifted its stake in shares of MindWalk by 147.3% during the 4th quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock worth $293,000 after purchasing an additional 96,018 shares during the last quarter. Bridgeway Capital Management LLC bought a new stake in MindWalk during the fourth quarter valued at about $91,000. Finally, XTX Topco Ltd grew its stake in MindWalk by 118.6% in the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock valued at $149,000 after purchasing an additional 44,331 shares during the last quarter. Institutional investors own 6.70% of the company’s stock.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.